Research programme: cytokine inhibitor therapeutics - Almirall/Mercachem

Drug Profile

Research programme: cytokine inhibitor therapeutics - Almirall/Mercachem

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mercachem
  • Developer Almirall S.A.; Mercachem
  • Class Small molecules
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 21 Dec 2016 Almirall in licenses cytokine blockers program from Mercachem
  • 21 Dec 2016 Early research in Inflammation in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top